Economic evaluation of pharmacist involvement in disease management in a community pharmacy setting

Clinical Therapeutics

Volumn 19, Issue 1, 1997, Pages 113-123

  Munroe, Wendy P ^a   Kunz, Kimberly ^b   Dalmady Israel, Christina ^a   Potter, Lori ^b   Schonfeld, Warren H ^b  

^a MedOutcomes Inc   (United States)

^b Technology Assessment Group   (United States)

Author keywords

community pharmacy; disease management; pharmaceutical care; pharmacoeconomics

Indexed keywords

ADULT; AGED; ARTICLE; ASTHMA; COMMUNITY CARE; CONTROLLED STUDY; COST; DIABETES MELLITUS; DISEASE MANAGEMENT; DRUG COST; DRUG USE; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MODEL; PATIENT EDUCATION; PHARMACIST; PHARMACY; PRESCRIPTION; TREATMENT OUTCOME;

EID: 0030956563     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80078-1     Document Type: Article

References (18)

1. Johnson JA, Bootman JL. Drug-related morbidity and mortality: A cost of illness model. Arch Intern Med. 1995;155: 1949-1956.
2. Berg JS, Dischler J, Wagner DJ, et al. Medication compliance: A health care problem. Ann Pharmacother. 1993;27 (Suppl):S5-S19.
3. Haskitt RL. Patient compliance: Tapping into a billion-dollar drug market. Pharmaceutical Exec. 1989;July:46-52.
4. Munroe WP. Clinical monitoring plans for the delivery of pharmaceutical care. J Am Pharm Assoc. 1996;NS36:397-402.
5. McKenney JA. Effect of pharmacist drug monitoring and patient education on hypertensive patients. Contemp Pharm Pract. 1978;1:50-56.
6. Brown DJ, Helling DK, Jones ME. Evaluation of clinical pharmacist consultation in the family practice office. Am J Hosp Pharm. 1979;36:912-915.
7. Rupp MT. Value of community pharmacists' interventions to correct prescribing errors. Ann Pharmacother. 1992;26: 1580-1584.
8. Kimberlin CL, Berardo DH, Pendergast JF. Effects of an education program for community pharmacists on detecting drug-related problems in elderly patients. Med Care. 1993;31:451-468.
9. McCombs JS, Cody M, Besinque K, et al. Measuring the impact of patient counseling in the outpatient pharmacy setting: The research design of the Kaiser Permanente/USC Patient Consultation Study. Clin Ther. 1995;17:1188-1206.
10. Park JJ, Kelly P, Carter BL, Burgess PP. Comprehensive pharmaceutical care in the chain setting. J Am Pharm Assoc. 1996; NS36:443-451.
11. MunRo Partners, Inc. Practice Protocols. Richmond, Va: MedOutcomes, Inc.; 1995.
12. MedOutcomes, Inc. Comprehensive Practice Guidelines. Richmond, Va: MedOutcomes, Inc.; 1995.
13. Fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
14. National High Blood Pressure Education Program Working Group report on primary prevention of hypertension. Arch Intern Med. 1993;153:186-208.
15. National Asthma Education Program Expert Panel. Guidelines for the diagnosis and management of asthma. National Institutes of Health, National Heart, Lung, and Blood Institute Pub. No. 91-3042. Bethesda, Md: United States Department of Health and Human Services; 1991.
16. National Cholesterol Education Program (NCEP) Expert Panel. Summary of the second report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA. 1993; 269:3015-3023.
17. American Diabetes Association. Clinical practice recommendations - 1992-1993. Diabetes Care. 1993;16(Suppl 2):1-113.
18. Oster G, Borok GM, Menzin J, et al. Cholesterol-reduction intervention study (CRIS). A randomized trial to assess effectiveness and costs in clinical practice. Arch Intern Med. 1996;156:731-739.